Patent details

LUC00351 Product Name: Rezafungin or a pharmaceutically acceptable salt thereof, in particular rezafungin acetate

Basic Information

Publication number:
LUC00351
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP127519940
Legal Status:
Inactive
Application number:
LUC00351
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/23/1775
Marketing Authorization Type:
Marketing Authorization Date:
22/12/2023
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
18/06/2024
First Marketing Authorization date:
22/12/2023
Grant date:
05/05/2026
Activation date:
Publication date:
18/06/2024
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
02/03/2037
SPC Extension Expiration:
02/03/2037
Rejection date:
Withdrawal date:

Owner

From:
18/06/2024
 
 

Name:
NAPP PHARMACEUTICAL GROUP LIMITED
Address:
Unit 191 Cambridge Science Park, Milton Road,, CB4 0GW, Cambridge, United Kingdom (GB)

Agent

Name:
Dennemeyer & Associates S.A.
From:
18/06/2024
Address:
55, rue des Bruyères, L-1274, HOWALD, Luxembourg (LU)
To:

Publication

Bulletin

Bulletin Heading:
SPC1
Bulletin edition number:
2024/09
Publication date:
11/07/2024
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

Annual Fees

Annual Fee Due Date:
31/03/2032
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
18/06/2024 Summary of the product caracteristics 26
18/06/2024 General Document 1
18/06/2024 MA publication 8
18/06/2024 General Document 44
18/06/2024 General Document 2
18/06/2024 Application Form 5
18/06/2024 Marketing authorization 3
19/06/2024 Outgoing Correspondence 1
25/06/2024 Administration 1
05/05/2026 Publication 1
05/05/2026 Certificate 1
05/05/2026 Outgoing Correspondence 1